Targeted Therapy for Brain Tumors
Targeted therapy is a personalized cancer treatment approach that uses medicines designed to act on specific molecular changes, proteins, or pathways involved in tumor growth. For selected patients with brain tumors, targeted treatment may be considered when testing identifies a biological feature that can be addressed with an appropriate targeted medicine.
Unlike conventional chemotherapy, which can affect many rapidly dividing cells, targeted therapies are developed to interact with particular characteristics of cancer cells. Treatment selection depends on the tumor type, location, grade, genetic or molecular profile, previous treatments, overall health, and the treating specialist’s assessment.
Who May Benefit From Targeted Therapy?
Targeted therapy may be considered for certain patients with brain tumors when molecular or genetic testing reveals a relevant treatment target. Your neurosurgical and oncology team may recommend tumor tissue analysis or other diagnostic tests before deciding whether targeted treatment is appropriate.
How Is Targeted Therapy Planned?
Treatment planning begins with a detailed evaluation of medical history, imaging studies, pathology reports, and available molecular test results. Depending on the diagnosis, targeted medicines may be used alone or alongside brain tumor surgery, radiation therapy, or other cancer treatments.
Benefits and Considerations
Potential benefits include a more individualized treatment strategy and the ability to focus therapy on specific tumor characteristics. However, targeted therapy is not suitable for every patient and may cause side effects or require regular monitoring. Your doctor will discuss expected benefits, possible risks, treatment duration, and follow-up requirements before treatment begins.
Ongoing Monitoring
Regular clinical reviews and imaging may be required to assess treatment response and monitor for side effects. Treatment may be adjusted based on how the tumor responds and how well the therapy is tolerated.
Patients should discuss all treatment options with a qualified neurosurgeon or oncology specialist before making decisions about targeted therapy.